Abstract: An anti-human PD-L1 nanobody and use thereof, and an anti-human PD-L1 and TLR7 double-targeting nanobody conjugate drug, a preparation method therefor and use thereof are provided. Specifically, provided are use and a solution of an anti-human PD-L1 nanobody and a derivative protein thereof for anti-tumor treatment, and also provided are design, preparation, and identification solutions for a novel anti-human PD-L1 and TLR7 double-targeting nanobody drug conjugate and a derivative molecule thereof and an effect thereof in anti-tumor treatment. The anti-human PD-L1 and TLR7 double-targeting nanobody drug conjugate can exert significant anti-tumor efficacy.

Abstract: The disclosure relates to a laser sight device, which includes a laser sight device housing, a laser sight device inner core, and a fine-tuning spring. A first arc-shaped elastic piece and a second arc-shaped elastic piece of the fine-tuning spring are respectively inserted into a laser sight device housing from corresponding openings, and a protrusion of the fine-tuning spring is inserted into a limit hole of the laser sight device housing. The first arc-shaped elastic piece and the second arc-shaped elastic piece are configured to cause a continuous and balanced force on the laser sight device inner core when adjusting an angle of the laser sight device inner core, and to reset the laser sight device inner core when the force is withdrawn.

Abstract: The disclosure relates to a micro gunsight, a small laser, a fine-tuning spring, a laser sight device inner core, a reset pin and a laser sight device. which includes a mounting slot that is matched with the gun card track. The mounting slot is composed of a fixed rail and a movable rail. The mounting slot is provided with a gunsight body, and inside the gunsight body is provided with a laser fine-tuning seat. A dual-light laser is installed inside the laser fine-tuning seat, and a fine-tuning mechanism is installed in the laser fine-tuning seat. There are multiple adapters at the bottom of the gunsight body, which are suitable for different Picatinny rails, making the installation position closer to the trigger guard, convenient for users to operate, and avoiding the problem of easy loosening of the front and rear positions of the sight device.

Abstract: An adjustment mechanism, comprising a left adjustment screw, a stop block threadedly connected to the left adjustment screw, and a right adjustment screw, also comprised are a sliding block a side surface of the front end of which is provided with a transverse sliding groove, a transverse mounting block having an LED chip module mounting base, and a wedge-shaped block; a limiting pin and a spiral reset spring sleeved on the limiting pin are provided at the end part of the right end of the transverse mounting block; the right adjustment screw is threadedly connected to a vertical side surface of the wedge-shaped block, a mounting groove for mounting the LED chip module mounting base is provided at the top part of the transverse sliding block, and a front end extending surface of the mounting groove communicates with the transverse sliding groove.

Abstract: A sight system based on a combination of infrared imaging, low-illumination imaging, and an LED sight light dot, comprising an LED graphics chip (20), a lens (3), a beam splitter (30), a display screen (31), a thermal imaging core assembly (13), a low-light night vision camera module (48), and a main control board (51). The thermal imaging core assembly (13) is electrically connected to the main control board (51), the low-light night vision camera module (48) is electrically connected to the main control board (51), the thermal imaging core assembly (13) and the low-light night vision camera module (48) are both electrically connected to the display screen (31), the main control board (51) is electrically connected to the LED graphics chip (20) and the display screen (31), separately, and light emitted from the LED graphics chip (20) and the display screen (31) is incident on the lens (3) after passing through the beam splitter (30).

Abstract: Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.

Abstract: The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test.

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate, disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and or MACE.

Abstract: In an example, a three-dimensional (3D) memory device includes a memory stack and a through stair contact (TSC). The memory stack includes interleaved conductive layers and dielectric layers. The memory stack includes stairs in a staircase region. The TSC extends through the memory stack in the staircase region. The TSC includes a first conductor layer and a first spacer circumscribing the first conductor layer. The first conductor layer of the TSC is insulated from the conductive layers of the memory stack by the first spacer.

Abstract: A memory device includes a plurality of memory cells and a periphery circuit. Each memory cell includes at least one first transistor, at least one first interconnection layer formed over the first transistor and in electrical contact with the at least one transistor, and at least one capacitor electrically coupled to the at least one first transistor through the at least one first interconnection layer. A routing structure disposed over the plurality of memory cells and the periphery circuit to electrically connect the plurality of memory cells and the periphery circuit. A second interconnection layer is disposed over the routing structure. The at least one capacitor is disposed between the routing structure and a topmost conductive layer of the at least one first interconnection layer. The second interconnection layer includes no more than one conductive layer.

Abstract: Disclosed in the present invention are a use of a combination of an anti-PD-L1 nanobody and a TLR7 small molecule agonist in anti-tumor treatment, and a PD-L1 and TLR7 double-targeting nanobody coupling drug, a preparation method therefor, and a use thereof. Specifically, disclosed in the present invention are a use and solution of a combination of an anti-PD-L1 nanobody and a derived protein thereof as well as a TLR7 small molecule agonist and a derived compound thereof in anti-tumor treatment. Meanwhile, disclosed in the present invention are design, preparation, and identification solutions for a novel PD-L1 and TLR7 double-targeting-nanobody drug conjugate and a derived molecule thereof, and an effect of the novel PD-L1 and TLR7 double-targeting nanobody drug conjugate in anti-tumor treatment. The PD-L1 and TLR7 double-targeting nanobody drug conjugate of the present invention can yield a significant antineoplastic efficacy in various transplantation tumor models.

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

Abstract: An open type fine-tuning sight, including a housing mainly provided with a straight portion and a lens mounting frame, and the housing includes an outer housing assembly and an inner housing assembly; the inner housing assembly is sleeved in an installation space of the outer housing assembly, and a front end of the inner housing assembly is connected to the front end of the outer housing assembly through a parallel connecting rod assembly; a vertical return spring sleeved on a connecting screw is arranged between the rear end of a base and the bottom surface of the straight portion, an elastic sheet is disposed between one side of a rear end of the base and one side of a rear end of the straight portion, which are cooperated with a fine-tuning mechanism to realize the adjustment of the pitch angle and the lateral angle of the inner shell assembly.